Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (4s,4as,5ar,12as)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
2. (4s,4as,5ar,12as)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide Dihydrochloride
3. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline
4. Eravacycline Dihydrochloride
5. Tp-434
6. Tp-434-046
7. Tp-434046
8. Tp434
9. Xerava
1. 1207283-85-9
2. Tp-434
3. Xerava
4. Eravacycline [usan]
5. Tp434
6. (4s,4as,5ar,12ar)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
7. Eravacycline (usan)
8. 07896928zc
9. 1-pyrrolidineacetamide, N-((5ar,6as,7s,10as)-9-(aminocarbonyl)-7-(dimethylamino)-4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl)-
10. Eravacycline [usan:inn]
11. Unii-07896928zc
12. Yqm
13. Tp434;eravacycline
14. Eravacycline [mi]
15. Eravacycline [inn]
16. Eravacycline [who-dd]
17. Chembl1951095
18. Chembl4597183
19. Schembl10040430
20. Gtpl10805
21. Ex-a751
22. Chebi:177804
23. Dtxsid401026285
24. Mfcd31010183
25. Zinc200151468
26. Cs-7564
27. Db12329
28. Compound 17j [pmid: 2148514]
29. Hy-16980
30. D10369
31. J-690064
32. Q15410941
33. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline
34. (4s,4as,5ar,12ar)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboxamide
35. (4s,4as,5ar,12ar)-4-(dimethylamino)-7-luoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
36. (4s,4as,5ar,12as)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
37. (4s,4as,5ar,12as)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
38. (4s,4as,5ar,12as)-4-(dimethylamino)-7-fluoro-3,10,12,12atetrahydroxy-1,11-dioxo-9-(2-(pyrrolidin-1-yl)acetamido)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
39. 4s,4as,5ar,12as)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
40. 7-[6-(2-hydroxy-2-propanyl)-3-pyridinyl]-1-(4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
41. N-[(5ar,6as,7s,10as)-9-(aminocarbonyl)-7-(dimethylamino)-4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide
Molecular Weight | 558.6 g/mol |
---|---|
Molecular Formula | C27H31FN4O8 |
XLogP3 | 1 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 5 |
Exact Mass | 558.21259212 g/mol |
Monoisotopic Mass | 558.21259212 g/mol |
Topological Polar Surface Area | 194 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 1200 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Eravacycline is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.
FDA Label
Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Eravacycline is an antibiotic that disrupts bacterial protein synthesis, treating complicated intraabdominal infections.
J01AA
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01A - Tetracyclines
J01AA - Tetracyclines
J01AA13 - Eravacycline
Absorption
Following single-dose intravenous administration, eravacycline AUC (area under the curve) and Cmax (maximum concentration) increase dose-proportionally for doses from 1 mg/kg - 3 mg/kg (3 times the approved dose). There is approximately 45% accumulation following intravenous dosing of 1 mg/kg every 12 hours.
Route of Elimination
Following a single intravenous dose of radiolabeled eravacycline 60 mg, approximately 34% of the dose is excreted in urine and 47% in feces as unchanged eravacycline (20% in urine and 17% in feces) and metabolites.
Volume of Distribution
The volume of distribution at steady-state is approximately 321 L.
Clearance
17.82 L/min (standard deviation of 3.4).
Eravacycline is metabolized primarily by CYP3A4- and FMO-mediated oxidation.
The mean elimination half-life is 20 hours.
Eravacycline is a fluorocycline antibacterial of the tetracycline class of antibacterial drugs. Eravacycline disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the incorporation of amino acid residues into elongating peptide chains. In general, eravacycline is bacteriostatic against gram-positive bacteria (e.g., Staphylococcus aureus and Enterococcus faecalis); however, in vitro bactericidal activity has been shown against certain strains of Escherichia coli and Klebsiella pneumoniae.
Global Sales Information
Market Place
ABOUT THIS PAGE
31
PharmaCompass offers a list of TP-434 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right TP-434 manufacturer or TP-434 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred TP-434 manufacturer or TP-434 supplier.
PharmaCompass also assists you with knowing the TP-434 API Price utilized in the formulation of products. TP-434 API Price is not always fixed or binding as the TP-434 Price is obtained through a variety of data sources. The TP-434 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Eravacycline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eravacycline, including repackagers and relabelers. The FDA regulates Eravacycline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eravacycline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Eravacycline manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Eravacycline supplier is an individual or a company that provides Eravacycline active pharmaceutical ingredient (API) or Eravacycline finished formulations upon request. The Eravacycline suppliers may include Eravacycline API manufacturers, exporters, distributors and traders.
click here to find a list of Eravacycline suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Eravacycline as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Eravacycline API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Eravacycline as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Eravacycline and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Eravacycline NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Eravacycline suppliers with NDC on PharmaCompass.
Eravacycline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Eravacycline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Eravacycline GMP manufacturer or Eravacycline GMP API supplier for your needs.
A Eravacycline CoA (Certificate of Analysis) is a formal document that attests to Eravacycline's compliance with Eravacycline specifications and serves as a tool for batch-level quality control.
Eravacycline CoA mostly includes findings from lab analyses of a specific batch. For each Eravacycline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Eravacycline may be tested according to a variety of international standards, such as European Pharmacopoeia (Eravacycline EP), Eravacycline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eravacycline USP).